Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PST in San Francisco. The company is known for its innovative solutions aimed at treating chronic diseases like sleep apnea and COPD, enhancing patients' quality of life through digital health technologies. Investors can access the live audio-only webcast and a replay will be available post-event for 30 days. ResMed operates in over 140 countries, focusing on out-of-hospital support systems.

ResMed has acquired MEDIFOX DAN, a leading German software solutions provider, for €958.6 million ($997.5 million). This strategic acquisition marks ResMed's first expansion of its SaaS business into Germany, the second largest healthcare market globally. MEDIFOX DAN will enhance ResMed's portfolio with outpatient therapy service offerings, and its operations will integrate within ResMed's SaaS segment. The acquisition is expected to be accretive to non-GAAP diluted earnings per share, while ResMed plans to retain all MEDIFOX DAN employees and maintain its current brand.

ResMed (NYSE: RMD) reported a 5% year-over-year revenue growth for Q1 2023, totaling $950.3 million, with a 9% increase on a constant currency basis. Operating profit rose 5%, while non-GAAP operating profit increased 4%. Diluted earnings per share increased to $1.43, with a non-GAAP EPS of $1.51. The company noted strong sales in the Americas and expanding gross margins despite increased SG&A expenses. Additionally, ResMed announced the acquisition of mementor and unveiled plans to double its R&D workforce in Ireland.

ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.

ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bank of America Global Healthcare Conference on September 14, 2022, at 9:05 a.m. BST in London. This event will be accessible via a live webcast, with a replay available approximately three hours after the event until December 13, 2022. ResMed continues to innovate with digital health technologies and cloud-connected medical devices, aiming to enhance the quality of life for patients suffering from chronic diseases globally.

ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET in New York City. The event will include a live webcast, with a replay available three hours after it concludes, accessible until March 11, 2023. ResMed focuses on innovative solutions for chronic diseases, aiming to improve quality of life and reduce healthcare costs globally.

ResMed's latest research reveals that over 480 million people globally suffer from chronic obstructive pulmonary disease (COPD), a prevalence significantly higher—by 22–126%—than previous estimates. This figure could escalate to 592 million by 2050 if current trends in smoking and air pollution continue. COPD costs the EU approximately €48.4 billion annually, with the U.S. facing over $3 billion in hospitalization costs alone. The study urges immediate action for better screening and treatment, stressing the importance of reducing risk factors associated with COPD.

ResMed reported a 4% increase in year-over-year revenue for Q4 2022, totaling $914.7 million. Operating profit rose 6%, with diluted earnings per share at $1.33. Annual revenue reached $3.6 billion, marking a 12% growth. Despite a 90 bps contraction in gross margin to 56.6%, non-GAAP measures showed resilience with an operating profit increase of 8% for the year. The board declared a 5% increase in dividends to $0.44 per share. The company is optimistic about growth in FY23, aided by new product launches and an upcoming acquisition of MEDIFOX DAN for $1 billion.

ResMed has acquired Leipzig-based mementor as of August 1, 2022, enhancing its digital sleep medicine portfolio in Germany. This strategic move integrates mementor’s somnio, a digital insomnia therapy solution, into ResMed's offerings, filling a significant care gap for patients suffering from insomnia. Somnio, which is the only permanently approved Digital Health Application (DiGA) for insomnia in Germany, is now available via prescription and eligible for reimbursement. This acquisition aims to expand access to effective sleep treatments and leverage ResMed's network for greater adoption.